Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism.
Prostaglandin E1 (PGE1) was used for diagnostic and therapeutic purposes in 149 men with erectile dysfunction over a period of 20 months (February 1987-October 1988). The intracavernous application of PGE1 in varying doses resulted in an erection sufficient for sexual intercourse in 79% of cases. In order to differentiate between vascular and non-vascular impotence, 5 micrograms PGE1 were found to be a sufficiently high and safe dose for the first intracavernous injection. Local discomfort, ranging from mild to severe pain after injection, was recorded in 40% of patients. A significant difference in severe side effects was found between arterial, venous and non-vasculogenic impotence, the highest incidence of local pain occurring in non-vasculogenic patients. The most striking result was the occurrence of 4 cases of priapism, all in the non-vascular group, 1 of these occurring after the injection of only 5 micrograms PGE1.
Schramek
P
P
Department of Urology, Allgemeine Poliklinik, Vienna, Austria.
Dorninger
R
R
Waldhauser
M
M
Konecny
P
P
Porpaczy
P
P
D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000009:adverse effects / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010410:Penile Erection / Q000187:drug effects*; D011317:Priapism / Q000139:chemically induced*
D000527:Alprostadil